NanoMosaic and Solid Biosciences agreed to comarket offerings to support gene therapy developers’ analytics workflows, pairing NanoMosaic’s Tessie platform with Solid’s Polaris-101 capsid targeting skeletal muscle and cardiac tissue. The deal is designed to promote standardized vector genome and capsid characterization during AAV manufacturing. Under the partnership, Solid’s capsid technology is paired with NanoMosaic’s multiplex plate reader approach, which measures full, partial, and empty capsids alongside transgene and capsid quantification using the same chip. NanoMosaic said it received FDA AMT designation earlier this year for Tessie. For developers, the goal is to improve safety, efficacy, and dosing decisions by tightening measurement confidence during vector production—an area increasingly scrutinized by regulators and sponsors as AAV therapies scale. Strategically, the comarketing tie-in signals that manufacturing analytics platforms are becoming core enablers in gene therapy delivery rather than optional add-ons.